Read by QxMD icon Read


Maurizio Pompili, Claudio Verzura, Giada Trovini, Andrea Buscajoni, Giulia Falcone, Stefano Naim, Adele Nardella, Serena Sorice, Ross J Baldessarini, Paolo Girardi
Lurasidone ([3aR,4S,7R,7aS]-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1yl-methyl] cyclohexylmethyl]-hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; Latuda®) is a novel benzisothiazole, second-generation antipsychotic drug developed by Dainippon Sumitomo Pharma Corporation in Japan. Similar to other atypical antipsychotics it has a distinctive pharmacodynamic profile, Areas covered: This review updates reported research findings on the efficacy, safety and tolerability of LRSD for treatment of psychotic and major affective disorders, with meta-analyses...
February 2018: Expert Opinion on Drug Safety
Heather Carey, Mark Fondriest
BACKGROUND: Newer atypical antipsychotics such as aripiprazole (Abilify, Otsuka) and lurasidone (Latuda, Sunovion) have favorable safety and efficacy profiles, but their use is limited by high cost. University Hospitals Richmond Medical Center initiated an antipsychotic tablet-splitting program in August 2015 to counter the costs based on the identical pricing structure of aripiprazole and lurasidone doses. METHODS: A retrospective chart review was completed for all patients dispensed aripiprazole or lurasidone oral tablets from May 1, 2015, through December 31, 2015, to evaluate the potential cost-savings for our facility...
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
(no author information available yet)
Lurasidone (Latuda-Sunovion) is a new oral second-generation antipsychotic licensed for treating adults with schizophrenia. Although less likely to cause extrapyramidal adverse effects than first-generation antipsychotics, some second-generation antipsychotics cause weight gain that may increase the risk of diabetes, hypertension and raised lipid levels.1,2 Lurasidone is promoted as offering a balance between efficacy and tolerability, with reported negligible effects on weight and minimal effects on glucose and cholesterol...
March 2015: Drug and Therapeutics Bulletin
Mark Sanford, Sohita Dhillon
Lurasidone (Latuda(®)), a benzisothiazole derivative antipsychotic, is approved in the USA and Canada for the treatment of adults with major depressive episodes (MDE) associated with bipolar I disorder; this article reviews studies of lurasidone in this indication. In two 6-week, placebo-controlled trials in adults with bipolar I depression, lurasidone 20-120 mg/day reduced depressive symptoms, either as monotherapy or as an adjunct to lithium or valproate. Lurasidone reduced the mean Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline (primary endpoint) by >50 %; the reductions in scores were significantly greater than with placebo...
March 2015: CNS Drugs
Corey R Hopkins
No abstract text is available yet for this article.
February 16, 2011: ACS Chemical Neuroscience
Shambria F Nolan, Marian W Roman
Lurasidone is a new atypical antipsychotic that has demonstrated positive effects on psychosis, mood, and cognition. This improved efficacy and safety profile for the treatment of schizophrenia. Its overall tolerability profile seems to be comparable to the other atypical antipsychotics. Perhaps its more potent blockade on the 5HT7 receptor will give it more of an advantage in treating the negative symptoms as well as improve cognitive and depressive symptoms associated with schizophrenia. Additionally, it does not appear to have any significant adverse impact on the metabolic profile, such as weight, glucose, or lipid metabolism...
May 2012: Issues in Mental Health Nursing
Eunice Y Yuen, Xiangning Li, Jing Wei, Masakuni Horiguchi, Herbert Y Meltzer, Zhen Yan
N-Methyl-D-aspartate (NMDA) receptor (NMDAR) hypofunction has been postulated to contribute to the cognitive deficit of schizophrenia. In this study, we examined the effect of lurasidone (Latuda; Dainippon Sumitomo Pharma Co. Ltd., Tokyo, Japan), a newly approved atypical antipsychotic drug (APD), on NMDAR synaptic function in rat frontal cortical pyramidal neurons. In vivo administration of lurasidone produced a significant and selective enhancement of NMDAR-mediated synaptic responses and surface expression of NR2A and NR2B subunits...
February 2012: Molecular Pharmacology
Martin P Cruz
No abstract text is available yet for this article.
August 2011: P & T: a Peer-reviewed Journal for Formulary Management
Robert H Howland
This article briefly reviews the novel atypical second-generation antipsychotic drugs iloperidone (Fanapt®), asenapine (Saphris®), and lurasidone (Latuda®), all of which have been approved by the U.S. Food and Drug Administration since 2009. Each is indicated for the treatment of schizophrenia, and asenapine has an additional indication for bipolar disorder. Very little information is available on their use in other disorders, pediatric and geriatric patients, and during pregnancy and breastfeeding. Their overall efficacy is no different than other antipsychotic drugs, but they do have different side effect profiles...
April 2011: Journal of Psychosocial Nursing and Mental Health Services
(no author information available yet)
No abstract text is available yet for this article.
February 21, 2011: Medical Letter on Drugs and Therapeutics
P A Richardson, L M Latuda
The rehabilitation process of an injured athlete can be accelerated if clinicians will use an imagery model in conjunction with existing therapeutic care. There is sufficient evidence to suggest a positive relationship between imagery and the healing process. Thus, we provide athletic trainers and practicing clinicians with basic information relating to the use of imagery in rehabilitation. Specifically, a sample imagery program is discussed incorporating the following prescribed steps: introducing imagery to the athlete, evaluating the athlete's imaging ability, assisting the athlete in developing basic imagery skills, and providing tips on the adjunctive use of imagery in a rehabilitation program...
March 1995: Journal of Athletic Training
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"